We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $2.35K invested in iTeos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 135 closing their positions.

New
Increased
Maintained
Reduced
Closed

98.8% less ownership

Funds ownership: 98.8% → 0% (-99%)

99% less funds holding

Funds holding: 136 → 1 (-135)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $377M → $2.35K (-$377M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 135

Holders
1
Holders Change
-135
Holders Change %
-99.26%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
135
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$20

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$107M
2
BlackRock
BlackRock
New York
-$45.6M
3
TCM
Tang Capital Management
California
-$38.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$16.6M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$8.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
– -$2.58M -258,369 Closed
Charles Schwab
27
Charles Schwab
California
– -$2.45M -246,086 Closed
AQR Capital Management
28
AQR Capital Management
Connecticut
– -$2.37M -237,805 Closed
AGM
29
Alpine Global Management
New York
– -$2.24M -225,000 Closed
SC
30
Shay Capital
New York
– -$2.1M -210,516 Closed
Ameriprise
31
Ameriprise
Minnesota
– -$2.07M -207,787 Closed
DP
32
Diadema Partners
New Jersey
– -$2.06M -206,200 Closed
SPS
33
Susquehanna Portfolio Strategies
Pennsylvania
– -$2.04M -204,708 Closed
Acadian Asset Management
34
Acadian Asset Management
Massachusetts
– -$1.86M -186,692 Closed
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
– -$1.85M -185,760 Closed
PLC
36
Peapod Lane Capital
New York
– -$1.69M -169,287 Closed
Goldman Sachs
37
Goldman Sachs
New York
– -$1.55M -155,351 Closed
Wellington Management Group
38
Wellington Management Group
Massachusetts
– -$1.54M -154,963 Closed
N
39
Nuveen
North Carolina
– -$1.54M -154,424 Closed
Verition Fund Management
40
Verition Fund Management
Connecticut
– -$1.5M -150,648 Closed
GCIA
41
Gabelli & Co Investment Advisers
New York
– -$1.46M -146,450 Closed
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
– -$1.44M -144,080 Closed
DCM
43
DAFNA Capital Management
California
– -$1.4M -140,847 Closed
Barclays
44
Barclays
United Kingdom
– -$1.26M -125,996 Closed
GF
45
Gabelli Funds
New York
– -$1.2M -120,593 Closed
EP
46
Eversept Partners
New York
– -$1.09M -109,324 Closed
Simplex Trading
47
Simplex Trading
Illinois
– -$1.03M -103,212 Closed
Citadel Advisors
48
Citadel Advisors
Florida
– -$940K -94,256 Closed
Invesco
49
Invesco
Georgia
– -$808K -81,035 Closed
American Century Companies
50
American Century Companies
Missouri
– -$787K -78,949 Closed
1
2
3 4 5

ITOS Hedge Fund Activity: Q3 2025 in Review

1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2025, worth a combined $2.35K — down 100% from $377M a quarter earlier.

Sellers outnumbered buyers: 135 funds closed out of ITOS and 0 opened new positions — a net loss of 135 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $20. The largest seller was EcoR1 Capital, exiting entirely with an estimated $107M sold.

  • 1 institutional investor held iTeos Therapeutics (ITOS) as of Q3 2025, down from 136 in Q2 2025.
  • Funds reported $2.35K of iTeos Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new iTeos Therapeutics positions in Q3 2025 and 135 closed out, a net change of -135 holders.
  • The largest iTeos Therapeutics buyer in Q3 2025 was IFP Advisors, an estimated $20 added.
  • The largest iTeos Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $107M sold.

Based on aggregated 13F filings for Q3 2025.